๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma

โœ Scribed by Etienne Chatelut; Christine Chevreau; Evelyne Blancy; Anne Lequellec; Pierre Canal; Henri Roche; Georges Houin; Roland Bugat

Publisher
Springer
Year
1990
Tongue
English
Weight
390 KB
Volume
26
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Cisplatin, etoposide, and mitomycin in t
Cisplatin, etoposide, and mitomycin in the treatment of non-small cell carcinoma of the lung. A pilot study
โœ Stephen Davis; Maurizio Tomato; Lucio Crino; Mari Antonetta Colozza; Kenneth Lub ๐Ÿ“‚ Article ๐Ÿ“… 1986 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 192 KB ๐Ÿ‘ 2 views

A total of 39 patients with non-small cell carcinoma of the lung (NSCL) were treated with cisplatin, etoposide, and mitomycin. A major response rate (complete response + partial response) was seen in 15 patients (39%). Median survival for all patients was 340 days; median survival of the responding

Paclitaxel, carboplatin, and extended sc
Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma
โœ John D. Hainsworth; Steven L. Stroup; F. Anthony Greco ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 577 KB

## BACKGROUND. Paclitaxel is an active agent in the initial treatment of patients with small cell lung carcinoma. The authors evaluated the toxicity and efficacy of paclitaxel (1-hour infusion) added to a standard combination regimen of carboplatin and etoposide in a Phase I1 trial for the treatme